137 results
8-K
EX-99.2
HROW
Harrow Inc
19 Mar 24
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
5:26pm
execute a branded pharma commercial strategy, followed by five subsequent transactions, two with Novartis, one with Santen, one with Sintetica (IHEEZO® … launch strategy amendments since its launch. Specifically, IHEEZO unit volumes and revenues ramped significantly during September (see graph below
8-K
EX-99.2
HROW
Harrow Inc
13 Nov 23
Harrow Announces Third Quarter 2023 Financial Results
4:34pm
, unit demand for IHEEZO began to increase markedly, a result of several successful launch strategy amendments since its launch. Specifically, IHEEZO … of these products are commercially available – see TRIESENCE Commentary below). Harrow’s strategy with these products, which had not been supported
8-K
EX-99.2
wdb dlzfd
9 Aug 23
Harrow Announces Second Quarter 2023 Financial Results
4:05pm
424B5
mb88m
19 Jul 23
Prospectus supplement for primary offering
5:19pm
424B5
zqdgrgw7mg7d r3n
18 Jul 23
Prospectus supplement for primary offering
5:03pm
8-K
EX-99.2
7zc ulbz6cdsf5rkl6
11 May 23
Harrow Announces First Quarter 2023 Financial Results
4:15pm
424B5
l2njxelk2limc jqqcv1
14 Dec 22
Prospectus supplement for primary offering
5:29pm
8-K
EX-99.2
xk6e6d3cv76bajlx
14 Nov 22
Harrow Announces Third Quarter 2022 Financial Results
4:20pm
8-K
EX-99.1
la5wcvg 8935
5 Oct 22
Other Events
5:27pm
8-K
EX-99.2
nymrtd34mf19
5 May 22
Harrow Health Announces First Quarter 2022 Financial Results
12:00am
8-K
EX-99.2
i2jp2cm fjt
10 Mar 22
Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results
4:30pm
8-K
EX-99.1
g4andzd4n42n5cz0erg
9 Dec 21
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded
4:13pm